Viridian Therapeutics, Inc. VRDN Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s other commercial liabilities?
- Viridian Therapeutics, Inc. (VRDN) reported other commercial liabilities of $38.49M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Viridian Therapeutics, Inc.'s other commercial liabilities increased by 30.2% year-over-year, from $29.55M to $38.49M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s other commercial liabilities has grown at a 44.9% compound annual growth rate (CAGR), from $9.7M to $62.01M.